Vasculitis: Current Status and Future Directions
Overview
Overview
Authors
Authors
Affiliations
Affiliations
Soon will be listed here.
Abstract
Vasculitides represent such a heterogeneous group of disorders that difficulties arise in their classification. Although biopsy examination of involved tissues remains essential, new serological markers have been developed. Therapeutic strategies have been refined, and B lymphocyte-targeted drugs may prove a satisfactory alternative.
References
1.
Taylor D
. Pharmacogenetics of beta2-agonist drugs in asthma. Clin Rev Allergy Immunol. 2006; 31(2-3):247-58.
DOI: 10.1385/CRIAI:31:2:247.
View
2.
Haney S, Hancox R
. Recovery from bronchoconstriction and bronchodilator tolerance. Clin Rev Allergy Immunol. 2006; 31(2-3):181-96.
DOI: 10.1385/CRIAI:31:2:181.
View
3.
Csernok E, Moosig F, Gross W
. Pathways to ANCA production: from differentiation of dendritic cells by proteinase 3 to B lymphocyte maturation in Wegener's granuloma. Clin Rev Allergy Immunol. 2008; 34(3):300-6.
DOI: 10.1007/s12016-007-8056-8.
View
4.
Smart B
. Is rhinosinusitis a cause of asthma?. Clin Rev Allergy Immunol. 2006; 30(3):153-64.
DOI: 10.1385/CRIAI:30:3:153.
View
5.
Toubi E
. The role of CD4+CD25+ T regulatory cells in autoimmune diseases. Clin Rev Allergy Immunol. 2007; 34(3):338-44.
DOI: 10.1007/s12016-007-8043-0.
View